Two studies [22,23] evaluated the LEPR Gln223Arg polymorphism in relation to breast cancer risk; one [22] in the Tunisia population reported significantly increased risk in both premenopausal and postmenopausal women in a dose dependent manner (OR = 1.68, 95% CI 1.12–2.50 and OR = 2.26, 95% CI 1.31–3.90 for the LEPR Gln223Arg and Arg223Arg genotypes, respectively). This evidence concerns the gene LEPR and breast carcinoma.